UPDATE: Piper Jaffray Downgrades Hansen Medical to Neutral on Continued Sales Uncertainty
May 09, 2013 at 11:10 AM EDT
In a report published Thursday, Piper Jaffray analyst Brooks E. West downgraded the rating on Hansen Medical (NASDAQ: HNSN ) from Overweight to Neutral, and lowered the price target from $3.00 to $1.50. In the report, West noted, “HNSN continues to face challenges commercializing the Magellan vascular system, with only